Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.54 |
| ▸ | HPRT1 | P00492 | 10/20 | 0.52 |
| ▸ | PNP | P00491 | 6/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leteprinim SCHEMBL358491 | 0.84 | HPRT1 (0.50) | HPRT1PNP | |
| Leteprinim SCHEMBL194355 | 0.83 | HPRT1 (0.49) | HPRT1PNP | |
| Leteprinim SCHEMBL6935182 | 0.83 | HPRT1 (0.49) | HPRT1PNP | |
| Leteprinim SCHEMBL6931317 | 0.83 | HPRT1 (0.49) | HPRT1PNP | |
| Hydrochloric Acid SCHEMBL7986516 | 0.83 | HPRT1 (0.46) | TK1HPRT1PNP | |
| SCHEMBL5250164 | 0.80 | TK1 (0.68) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL7689210 | 0.80 | MAPT (0.44) | USP2 | |
| SCHEMBL10506668 | 0.79 | PNP (0.76) | TK1PNPUSP2TSHREDNRA | |
| SCHEMBL7567095 | 0.78 | TK1 (0.60) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL7575116 | 0.78 | TK1 (0.59) | TK1HPRT1PNPUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1334103-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | claimed |
| EP-1334104-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | claimed |
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | NEOTHERAPEUTICS, INC. | 2002-09-12 | — | — | US | claimed |
| EP-1237890-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | Neotherapeutics, Inc. (US) | 2002-09-11 | — | — | EP | claimed |
| WO-2001028545-A9 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | NEOTHERAPEUTICS INC (US) | 2002-08-15 | — | — | WO | claimed |
| EP-1225877-A2 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | Neotherapeutics, Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| US-20020061899-A1 | Methods for treatment of drug-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | claimed |
| US-20020055506-A1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | claimed |
| US-20020040031-A1 | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system | NEO THERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | NEOTHERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| WO-2002004450-A2 | METHODS FOR PREVENTION OF ACCUMULATION OF AMYLOID BETA PEPTIDE IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004449-A2 | METHODS FOR TREATMENT OF CONDITIONS AFFECTED BY ACTIVITY OF MULTIDRUG TRANSPORTERS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004452-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004451-A2 | METHODS FOR STIMULATION OF SYNTHESIS OF SYNAPTOPHYSIN IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004448-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| US-6338963-B1 | GENE EXPRESSION OF MOLECULES IN MAMMALS | NEOTHERAPEUTICS, INC. | 2002-01-15 | — | — | US | claimed |
| US-6297226-B1 | TREATING A DISEASE OR A CONDITION IN A MAMMAL TREATABLE BY INHIBITING THE ACTIVITY OF A MONOAMINE OXIDASE | NEOTHERAPEUTICS, INC. | 2001-10-02 | — | — | US | claimed |
| WO-2001029039-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | claimed |
| WO-2001028545-A2 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | claimed |
| EP-1790344-A2 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | Spectrum Pharmaceuticals, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-6630490-B2 | Purine derivative or analogue | NEOTHERAPEUTICS, INC. | 2003-10-07 | — | — | US | disclosed |
| US-6630478-B2 | Administering to patient with drug-induced peripheral neuropathy an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue | NEOTHERAPEUTICS, INC. | 2003-10-07 | — | — | US | disclosed |
| EP-1334103-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1334104-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | Neotherapeutics, Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | NEOTHERAPEUTICS, INC. | 2002-09-12 | — | — | US | disclosed |
| EP-1237890-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | Neotherapeutics, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001028545-A9 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | NEOTHERAPEUTICS INC (US) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002058736-A2 | USE OF 9-SUBSTITUTED PURINE ANALOGUES AND OTHER MOLECULES TO STIMULATE NEUROGENESIS | NEOTHERAPETICS, INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-1225877-A2 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | Neotherapeutics, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020091133-A1 | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis | EVE M. TAYLOR | 2002-07-11 | — | — | US | disclosed |
| US-20020061899-A1 | Methods for treatment of drug-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| US-20020055506-A1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | SPECTRUM PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | disclosed |
| US-20020040031-A1 | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system | NEO THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | NEOTHERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002004449-A2 | METHODS FOR TREATMENT OF CONDITIONS AFFECTED BY ACTIVITY OF MULTIDRUG TRANSPORTERS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004451-A2 | METHODS FOR STIMULATION OF SYNTHESIS OF SYNAPTOPHYSIN IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004452-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004450-A2 | METHODS FOR PREVENTION OF ACCUMULATION OF AMYLOID BETA PEPTIDE IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004448-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| US-6338963-B1 | GENE EXPRESSION OF MOLECULES IN MAMMALS | NEOTHERAPEUTICS, INC. | 2002-01-15 | — | — | US | disclosed |
| US-6297226-B1 | TREATING A DISEASE OR A CONDITION IN A MAMMAL TREATABLE BY INHIBITING THE ACTIVITY OF A MONOAMINE OXIDASE | NEOTHERAPEUTICS, INC. | 2001-10-02 | — | — | US | disclosed |
| WO-2001029039-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029039-A1 | SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001028545-A2 | USE OF CARBON MONOXIDE DEPENDENT GUANYLYL CYCLASE MODIFIERS TO STIMULATE NEURITOGENESIS | NEOTHERAPEUTICS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061899-A1 | Methods for treatment of drug-induced peripheral neuropathy and related conditions | TYMP, TYMS, NGF | TK1 4/4885HPRT1 33/4885PNP 46/4885 |
| US-20020055506-A1 | Methods for treatment of disease-induced peripheral neuropathy and related conditions | NGF, NUDT1, HPRT1 | TK1 37/4885HPRT1 3/4885PNP 18/4885 |
| US-20020040032-A1 | Methods for stimulation of synthesis of synaptophysin in the central nervous system | GAP43, BDNF, APP | TK1 203/4885HPRT1 42/4885PNP 29/4885 |
| US-20020128264-A1 | Methods for treatment of conditions affected by activity of multidrug transporters | SLC29A1, ABCB1, NUDT1 | TK1 137/4885HPRT1 8/4885PNP 6/4885 |
| US-20020091133-A1 | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis | DCX, MKI67, TK2 | TK1 35/4885HPRT1 825/4885PNP 688/4885 |
| US-20020040031-A1 | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system | APP, BACE1, SARNP | TK1 251/4885HPRT1 10/4885PNP 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.